Compile Data Set for Download or QSAR
Report error Found 58 Enz. Inhib. hit(s) with all data for entry = 12085
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677028(US11993596, Compound WX064 | US20240294526, Compou...)
Affinity DataIC50: 0.0100nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677007(US11993596, Compound WX016 | US20240294526, Compou...)
Affinity DataIC50: 0.0100nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677015(US11993596, Compound WX026 | US20240294526, Compou...)
Affinity DataIC50: 0.0100nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677001(US11993596, Compound WX002 | US20240294526, Compou...)
Affinity DataIC50: 0.0200nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677019(US11993596, Compound WX048 | US20240294526, Compou...)
Affinity DataIC50: 0.0300nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677024(US11993596, Compound WX054 | US20240294526, Compou...)
Affinity DataIC50: 0.0300nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677016(US11993596, Compound WX036 | US20240294526, Compou...)
Affinity DataIC50: 0.0300nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677013(US11993596, Compound WX024 | US20240294526, Compou...)
Affinity DataIC50: 0.0400nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677013(US11993596, Compound WX024 | US20240294526, Compou...)
Affinity DataIC50: 0.0400nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677025(US11993596, Compound WX055 | US20240294526, Compou...)
Affinity DataIC50: 0.0400nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677000(US11993596, Compound WX001 | US20240294526, Compou...)
Affinity DataIC50: 0.0410nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677009(US11993596, Compound WX018 | US20240294526, Compou...)
Affinity DataIC50: 0.0500nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677020(US11993596, Compound WX049 | US20240294526, Compou...)
Affinity DataIC50: 0.0500nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677014(US11993596, Compound WX025 | US20240294526, Compou...)
Affinity DataIC50: 0.0900nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677018(US11993596, Compound WX047 | US20240294526, Compou...)
Affinity DataIC50: 0.100nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677003(US11993596, Compound WX004 | US20240294526, Compou...)
Affinity DataIC50: 0.120nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677026(US11993596, Compound WX056 | US20240294526, Compou...)
Affinity DataIC50: 0.140nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677018(US11993596, Compound WX047 | US20240294526, Compou...)
Affinity DataIC50: 0.160nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677022(US11993596, Compound WX052 | US20240294526, Compou...)
Affinity DataIC50: 0.180nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677004(US11993596, Compound WX005 | US20240294526, Compou...)
Affinity DataIC50: 0.180nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677007(US11993596, Compound WX016 | US20240294526, Compou...)
Affinity DataIC50: 0.240nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677021(US11993596, Compound WX050 | US20240294526, Compou...)
Affinity DataIC50: 0.240nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677012(US11993596, Compound WX021 | US20240294526, Compou...)
Affinity DataIC50: 0.25nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677006(US11993596, Compound WX015 | US20240294526, Compou...)
Affinity DataIC50: 0.260nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677019(US11993596, Compound WX048 | US20240294526, Compou...)
Affinity DataIC50: 0.270nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677008(US11993596, Compound WX017 | US20240294526, Compou...)
Affinity DataIC50: 0.280nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677009(US11993596, Compound WX018 | US20240294526, Compou...)
Affinity DataIC50: 0.280nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677020(US11993596, Compound WX049 | US20240294526, Compou...)
Affinity DataIC50: 0.300nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677027(US11993596, Compound WX057 | US20240294526, Compou...)
Affinity DataIC50: 0.310nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677016(US11993596, Compound WX036 | US20240294526, Compou...)
Affinity DataIC50: 0.410nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677008(US11993596, Compound WX017 | US20240294526, Compou...)
Affinity DataIC50: 0.430nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677014(US11993596, Compound WX025 | US20240294526, Compou...)
Affinity DataIC50: 0.440nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677011(US11993596, Compound WX020 | US20240294526, Compou...)
Affinity DataIC50: 0.470nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677010(US11993596, Compound WX019 | US20240294526, Compou...)
Affinity DataIC50: 0.480nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677022(US11993596, Compound WX052 | US20240294526, Compou...)
Affinity DataIC50: 0.5nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677017(US11993596, Compound WX037 | US20240294526, Compou...)
Affinity DataIC50: 0.510nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677010(US11993596, Compound WX019 | US20240294526, Compou...)
Affinity DataIC50: 0.530nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677006(US11993596, Compound WX015 | US20240294526, Compou...)
Affinity DataIC50: 0.560nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677023(US11993596, Compound WX053 | US20240294526, Compou...)
Affinity DataIC50: 0.570nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677003(US11993596, Compound WX004 | US20240294526, Compou...)
Affinity DataIC50: 0.630nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677005(US11993596, Compound WX010 | US20240294526, Compou...)
Affinity DataIC50: 0.650nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677011(US11993596, Compound WX020 | US20240294526, Compou...)
Affinity DataIC50: 0.650nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677002(US11993596, Compound WX003 | US20240294526, Compou...)
Affinity DataIC50: 0.660nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677021(US11993596, Compound WX050 | US20240294526, Compou...)
Affinity DataIC50: 1.10nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677012(US11993596, Compound WX021 | US20240294526, Compou...)
Affinity DataIC50: 1.10nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677028(US11993596, Compound WX064 | US20240294526, Compou...)
Affinity DataIC50: 1.40nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677017(US11993596, Compound WX037 | US20240294526, Compou...)
Affinity DataIC50: 1.70nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677023(US11993596, Compound WX053 | US20240294526, Compou...)
Affinity DataIC50: 1.90nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677025(US11993596, Compound WX055 | US20240294526, Compou...)
Affinity DataIC50: 2.10nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B(Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM677002(US11993596, Compound WX003 | US20240294526, Compou...)
Affinity DataIC50: 2.20nMAssay Description:Experimental objective: to determine the AMP/GMP expression based on fluorescence polarization, i.e., to trace binding of AMP/GMP to antibody so as t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 58 total ) | Next | Last >>
Jump to: